Neopharma to develop and market Pfizer products

Abu Dhabi’s Neopharma, which is part of NMC Healthcare Group, will develop, manufacture and market a wide-range of infective, gastrointestinal and other medicines for Wyeth, a Pfizer company.



By Haseeb Haider

Published: Tue 20 May 2014, 11:15 PM

Last updated: Tue 7 Apr 2015, 10:35 PM

Shaikh Nahyan bin Mubarak Al Nahyan addressing the gathering at the signing ceremony of the partnership agreement between Pfizer and Neopharma in Abu Dhabi on Monday. — KT photo by Shoaib Anwer

Neopharma, which has developed and registered with the UAE’s Ministry of Health, two products would soon start the manufacturing of Wyeth products, which will be marketed and distributed locally. These products and several others which will be produced in Abu Dhabi in future will be marketed and distributed by Wyeth through its own network in the 12 Middle Eastern nations.

Both pharmaceuticals signed a landmark long-term partnership agreement in the capital on Monday, which will boost the industrial capabilities of the Emirates and greatly help in economic diversification. The medicines, which will be produced at Neopharma’s production plant, will be available in many markets in the region starting in the market in 2015. Shaikh Nahyan bin Mubarak Al Nahyan, Minister of Culture, Youth and Community Development, in his speech welcomed the initiative which will boost the productivity in the country. Dr B.R. Shetty, Founder, Managing Director and CEO of Abu Dhabi-based Neopharama, said that the partnership aims to meet the unmet needs of patients and will focus primarily on diseases that residents suffer from across the region, such as cardiovascular diseases including hypertension and heart diseases. Other products include anti-inflammatory, pain management, women’s health and anti-infective drugs, he said.

Dr Shetty said: “With Pfizer and Neopharma working together, we witness the formation of collaborative efforts across manufacturing and distribution. This partnership will allow Pfizer’s research driven process and Neopharma’s world class manufacturing and regional expertise to work in synergy to make Abu Dhabi a hub in bringing leading therapies to the regional markets.”

“This is a dream come true and an important milestone in contributing back to Abu Dhabi which has been my motherland for 42 years now,” he said.

Speaking on the occasion Dr Zeydan Abuissa, Country Manager & Pfizer Global Established Pharma Lead Gulf and Levant, said this latest partnership highlights the importance Pfizer through its Wyeth Company places on its commitment to the UAE and wider Gulf region by providing reliable medication to patients here on the ground.

He said the strategic mix of Pfizer’s international experience with Neopharma’s local manufacturing capabilities enriches not only his firm’s presence here, but supports the UAE’s healthcare strategy by improving the quality of the healthcare systems provided to the greater benefit of the patients. “The partnership will enable us to transfer skills and knowledge locally as we foster, develop and successfully blending established international experiences with local unmet patients’ needs to enhance the UAE’s and the region knowledge based economy and develop local talent”, added Dr Zeydan.

— haseeb@khaleejtimes.com


More news from Local Business